J&J Eyes 'Imminent' Coronavirus Vaccine Production, Aims for a Billion Doses Worldwide - GV Wire - Explore. Explain. Expose
Connect with us

Aggregation

J&J Eyes 'Imminent' Coronavirus Vaccine Production, Aims for a Billion Doses Worldwide

Published

on

Photo of a doctor with a vaccine
Share with friends


Johnson & Johnson (JNJ) said on Tuesday it plans to begin imminent production of its trial COVID-19 vaccine on an “at risk” basis, as the coronavirus pandemic infects nearly 2 million people around the world.
Manufacturing “at risk” allows the world’s third largest pharmaceutical company to produce a product before its ultimate design is finalized and released to the public. The company plans to produce its COVID-19 vaccine in the Netherlands, and a facility it is updating in the United States.
“We’re manufacturing at risk to ensure that should the clinical development and the trials be successful, we are in a position to kind of flip the switch and ready to go, to create great access across the globe,” J&J CFO Joe Wolk told Yahoo Finance in an interview.
Read More →